PCSK9 Inhibitors

Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.

Also Known As:

Networked: 468 relevant articles (43 outcomes, 79 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Banach, Maciej: 9 articles (04/2021 - 01/2017)
2.	Sahebkar, Amirhossein: 8 articles (08/2021 - 08/2013)
3.	Santos, Raul D: 7 articles (09/2021 - 01/2016)
4.	Hegele, Robert A: 6 articles (01/2022 - 01/2018)
5.	Scicali, Roberto: 6 articles (01/2022 - 01/2020)
6.	Cariou, Bertrand: 6 articles (01/2020 - 06/2011)
7.	Di Pino, Antonino: 5 articles (01/2022 - 01/2020)
8.	Piro, Salvatore: 5 articles (01/2022 - 01/2020)
9.	Purrello, Francesco: 5 articles (01/2022 - 01/2020)
10.	Rodondi, Nicolas: 5 articles (01/2022 - 01/2016)

Related Diseases

1.	Cardiovascular Diseases (Cardiovascular Disease) 03/13/2023 - "Clinical trials regarding PCSK9 inhibitors have demonstrated a reduction in atherosclerotic cardiovascular disease events. " 01/01/2022 - "This review systematically summarized the application, preclinical studies, safety, mechanism of action, and latest research progress of PCSK9 inhibitors, aiming to provide ideas for the drug research and development and the clinical application of PCSK9 in cardiovascular diseases and expand its application in other diseases." 06/01/2014 - "The results of ongoing trials with CETP and PCSK9 inhibitors may warrant a wider employment in different categories of patients at high risk for cardiovascular disease. " 01/01/2022 - "Conversely, changes of HDL-C [MD = 6.27, CI (5.17 to 7.36), P < 0.00001] and ApoA1 [MD = 4.33, 95% CI (3.53 to 5.13), P < 0.00001] from baseline were significantly more in high cardiovascular disease risk patients who received PCSK9 inhibitors treatment. " 08/26/2021 - "We evaluated whether the price reduction would improve prescribing patterns of PCSK9 inhibitors in eligible patients with atherosclerotic cardiovascular disease (ASCVD). "
2.	Hypercholesterolemia 05/01/2022 - "The purpose of this trial was to determine the efficacy of PCSK9 inhibitors alone in patients with isolated hypercholesterolemia. " 12/09/2017 - "Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials." 06/15/2015 - "Randomized controlled trials of at least 8 weeks duration using PCSK9 inhibitors in treating patients with hypercholesterolemia were included. " 06/01/2011 - "PCSK9 has emerged as a new pharmacological target for hypercholesterolemia, and different PCSK9 inhibitors are now evaluated in clinical trials. " 07/13/2023 - "Correction to "Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment"."
3.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 08/23/2023 - "This review discusses whether patients' genotype affects the efficacy of PCSK9 inhibitors in treating familial hypercholesterolemia and how this might influence clinical management. " 08/23/2023 - "Does Genotype Affect the Efficacy of PCSK9 Inhibitors in the Treatment of Familial Hypercholesterolemia?" 07/01/2021 - "Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience." 06/24/2021 - "[The relationship between genotype of familial hypercholesterolemia and the efficacy of PCSK9 inhibitors]." 04/01/2023 - "The purpose of this narrative review is to synthesize all existing qualitative and quantitative data on the utility of PCSK9 inhibitors in familial hypercholesterolemia, in order to clarify standards of care and identify areas needing further research. "
4.	Stroke (Strokes) 01/01/2021 - "We searched PubMed, Embase, Cochrane Library, Web of Science, and ClinicalTrials.gov for research published until December 30, 2020, to find randomized controlled trials (RCTs) of PCSK9 inhibitors for brain stroke prevention. " 12/01/2020 - "Similarly, PCSK9 inhibitors treatment resulted in a 25% reduction of stroke (RR: 0.75, 95% CI 0.65-0.85) when all studies were analyzed together and the statistically significant heterogeneity was not observed in the analysis restricted to end-point based clinical trials. " 01/01/2020 - "Our data may act as a useful guide for sample size selection in future stroke trials testing PCSK9 inhibitors." 11/01/2021 - "Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention." 01/01/2021 - "There was no significant difference in cardiovascular mortality (RR, 0.95; 95% CI, 0.84-1.07; P = 0.382) and the risk of hemorrhagic brain stroke (RR, 1.00; 95% CI, 0.66-1.51; P = 0.999) between patients treated with PCSK9 inhibitors and controls. "
5.	Myocardial Infarction 10/24/2022 - "This study aims to investigate the efficacy and safety of in-hospital initiation of PCSK9 inhibitors among patients with acute myocardial infarction (AMI) based on real-world experience. " 01/01/2018 - "Conclusion PCSK9 inhibitors were ranked as the most effective treatment for reducing major adverse cardiovascular events, myocardial infarction and stroke, without having major safety concerns. " 01/01/2018 - "Results In network meta-analysis of 189,116 patients, PCSK9 inhibitors were ranked as the best treatment for prevention of major adverse cardiovascular events (Surface Under Cumulative Ranking Curve (SUCRA), 85%), myocardial infarction (SUCRA, 84%) and stroke (SUCRA, 80%). " 12/01/2020 - "we performed a meta-analysis, with currently available studies involving PCSK9 inhibitors and event rate adjudication, with the aim of assessing treatment effects on myocardial infarction and stroke. " 12/01/2020 - "Prevention of myocardial infarction and stroke with PCSK9 inhibitors treatment: a metanalysis of recent randomized clinical trials."

Related Drugs and Biologics

1.	Lipids
2.	oxidized low density lipoprotein
3.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
4.	LDL Cholesterol
5.	Subtilisin
6.	Proprotein Convertase 9
7.	Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)
8.	Ezetimibe (Zetia)
9.	evolocumab
10.	alirocumab

Related Therapies and Procedures

1.	Therapeutics
2.	Secondary Prevention
3.	Blood Component Removal (Apheresis)
4.	Aftercare (After-Treatment)
5.	Contraindications